Product
Palbocicilib
1 clinical trial
2 indications
Indication
Clear Cell Renal CarcinomaIndication
Papillary Renal Cell CarcinomaClinical trial
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)Status: Recruiting, Estimated PCD: 2025-06-01